Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Global Markets Direct
33 Pages - GMD16356
$1,500.00

Summary

Global Markets Direct’s, ‘Viamet Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Viamet Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Viamet Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Viamet Pharmaceuticals, Inc.
- The report provides overview of Viamet Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Viamet Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Viamet Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Viamet Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Viamet Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Viamet Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Viamet Pharmaceuticals, Inc. Snapshot 5
Viamet Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Viamet Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Viamet Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Viamet Pharmaceuticals, Inc. - Pipeline Products Glance 10
Viamet Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Viamet Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Viamet Pharmaceuticals, Inc. - Drug Profiles 13
VT-1161 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
VT-1129 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecules for Oncology 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecules for Orphan Diseases 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
VT-1598 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
VT-1607 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
VT-1654 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
VT-1658 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
VT-1669 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VT-1681 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Viamet Pharmaceuticals, Inc. - Pipeline Analysis 24
Viamet Pharmaceuticals, Inc. - Pipeline Products by Target 24
Viamet Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25
Viamet Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26
Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27
Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates 28
Viamet Pharmaceuticals, Inc. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

List of Tables
Viamet Pharmaceuticals, Inc., Key Information 5
Viamet Pharmaceuticals, Inc., Key Facts 5
Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016 7
Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 8
Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 9
Viamet Pharmaceuticals, Inc. - Phase II, 2016 10
Viamet Pharmaceuticals, Inc. - Phase I, 2016 11
Viamet Pharmaceuticals, Inc. - Preclinical, 2016 12
Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016 24
Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 25
Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 26
Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 27
Viamet Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 28

List of Figures
Viamet Pharmaceuticals, Inc. - Pipeline by Indication, 2016 7
Viamet Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 8
Viamet Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 9
Viamet Pharmaceuticals, Inc. - Pipeline by Target, 2016 24
Viamet Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 25
Viamet Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 26
Viamet Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 27

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838